Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome

P. L. Venturini, M. P. Alibrandi, S. Costantini, G. Gaggero, L. Penna, M. Valenzano, N. Ragni

Research output: Contribution to journalArticle


Although the role of dopaminergic system in the regulation of LH secretion is not fully established, the weight of evidence supports an inhibitory role. Yen (1980) showed that dopamine infusion decreases plasma LH levels in women with PCO Syndrome. It is known that Nomifensine activates central dopaminergic neurotransmission via presynaptic events without directly affecting DA receptors sites. In 15 polycystic ovary syndrome cases, Nomifensine failed to decrease basal and GnRH stimulated LH levels, although PRL levels were lowered. Although the increased dopaminergic activity was showed by PRL decrease, central dopaminergic activation had no effect on LH secretion. The finding may be explained by the predominant effect of DA system on physiological control of PRL secretion compared with the effects on LH secretion. Moreover in PCO patients pituitary sensitivity to GnRH is increased and in this pathological condition activation of central DA system may not lower the LH level. These results showed that Nomifensine induced central dopamine activation but did not influence basal and stimulated LH levels in PCO Syndrome.

Original languageEnglish
Pages (from-to)295-297
Number of pages3
JournalActa Europaea Fertilitatis
Issue number3
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome'. Together they form a unique fingerprint.

  • Cite this

    Venturini, P. L., Alibrandi, M. P., Costantini, S., Gaggero, G., Penna, L., Valenzano, M., & Ragni, N. (1981). Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome. Acta Europaea Fertilitatis, 12(3), 295-297.